Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

ClinicalTrials.gov ID: NCT07479797

Public ClinicalTrials.gov record NCT07479797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.

Study identification

NCT ID: NCT07479797
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Kite, A Gilead Company; Industry
Enrollment: 550 participants

Conditions and interventions

Conditions

Relapsed or Refractory Large B-cell Lymphoma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 21, 2026
Primary completion: Apr 30, 2031
Completion: Apr 30, 2031
Last update posted: Sep 3, 2026

2026 – 2031

United States locations

U.S. sites: 14
U.S. states: 13
U.S. cities: 14

Facility	City	State	ZIP	Site status
City of Hope Arizona	Goodyear	Arizona	85338	Recruiting
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)	Duarte	California	91010	Recruiting
Stanford University	Stanford	California	94305	Recruiting
Colorado Blood Cancer Institute	Denver	Colorado	80218	Recruiting
Yale University School of Medicine	New Haven	Connecticut	06510	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta	Newnan	Georgia	30265	Recruiting
City of Hope - Chicago	Zion	Illinois	60099	Recruiting
Washington University	St Louis	Missouri	63110	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Novant Health Cancer Institute - Hematology	Charlotte	North Carolina	28204	Recruiting
Henry-Joyce Cancer Clinic	Nashville	Tennessee	37203	Recruiting
St. David's South Austin Medical Center	Austin	Texas	78704	Recruiting
West Virginia University	Morgantown	West Virginia	26506	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07479797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 3, 2026 · Synced Sep 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07479797 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →